Hantz Financial Services Inc. Acquires 236 Shares of Bio-Techne Co. (NASDAQ:TECH)

Hantz Financial Services Inc. lifted its stake in Bio-Techne Co. (NASDAQ:TECH) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,196 shares of the biotechnology company’s stock after buying an additional 236 shares during the period. Hantz Financial Services Inc.’s holdings in Bio-Techne were worth $1,023,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in TECH. Public Sector Pension Investment Board lifted its position in shares of Bio-Techne by 76.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 6,130 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 2,649 shares during the period. Squarepoint Ops LLC raised its stake in Bio-Techne by 90.3% in the second quarter. Squarepoint Ops LLC now owns 32,334 shares of the biotechnology company’s stock valued at $2,317,000 after purchasing an additional 15,345 shares in the last quarter. Creative Planning lifted its position in Bio-Techne by 4.4% during the second quarter. Creative Planning now owns 33,942 shares of the biotechnology company’s stock worth $2,432,000 after purchasing an additional 1,437 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Bio-Techne by 12.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,917 shares of the biotechnology company’s stock worth $137,000 after buying an additional 205 shares in the last quarter. Finally, Quarry LP raised its position in shares of Bio-Techne by 2,275.6% in the 2nd quarter. Quarry LP now owns 974 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 933 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the transaction, the chief executive officer now owns 39,004 shares of the company’s stock, valued at $3,014,619.16. This represents a 25.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.90% of the company’s stock.

Bio-Techne Stock Performance

TECH opened at $73.55 on Friday. The company has a market cap of $11.69 billion, a price-to-earnings ratio of 78.25, a PEG ratio of 5.30 and a beta of 1.27. The company’s fifty day moving average price is $74.72 and its two-hundred day moving average price is $74.48. Bio-Techne Co. has a 1-year low of $61.16 and a 1-year high of $85.57. The company has a current ratio of 4.56, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.04. The business had revenue of $289.46 million during the quarter, compared to the consensus estimate of $280.22 million. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.35 EPS. On average, analysts expect that Bio-Techne Co. will post 1.68 EPS for the current fiscal year.

Analyst Ratings Changes

TECH has been the topic of a number of recent analyst reports. Scotiabank lifted their price objective on shares of Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a research note on Thursday, October 31st. StockNews.com raised Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Robert W. Baird raised their price objective on Bio-Techne from $82.00 to $84.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $82.00.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.